Wegovy in Birmingham, AL
Most weight loss medications start their life doing something else. Ozempic and Mounjaro were approved for diabetes, and both of them produce weight loss as a documented secondary effect. Wegovy is different. It was developed and FDA-approved specifically for chronic weight management in adults with obesity or overweight with weight-related health conditions.
That distinction matters more than it might seem on the surface. It means the dosing is calibrated specifically for weight loss rather than blood sugar management. It means the clinical trials behind it were designed around weight outcomes rather than metabolic markers. And it means that when you’re prescribed Wegovy, you’re taking a medication that was purpose-built for exactly what you’re trying to accomplish — with a board-certified surgeon overseeing every step of the process.
Who is Wegovy For?
Built for weight management, but not right for everyone.Wegovy’s FDA approval tells you something useful about who it was designed for. This medication was approved for weight management as the primary goal. That means the critical criteria for who qualifies are based on weight and health, not blood sugar levels. Here’s a general picture of who tends to be a strong fit:
As with every medication decision at Alabama Center for Weight Loss, the recommendation you receive will be based on your full health picture, not a general profile.
Wegovy is one of several weight loss options we provide. If you’re still exploring, here’s what else is available:
Frequently Asked Questions About Wegovy
Our weight loss injection program is cash-pay. While Wegovy has stronger insurance coverage potential than Ozempic or Mounjaro for weight loss, coverage is still inconsistent and often requires extensive documentation.
We’ve structured our program to remove that uncertainty; simple cash-pay pricing with no prior authorization delays. We’ll walk you through cost expectations during your consultation.
Wegovy and Ozempic share an active ingredient, semaglutide, but they’re not the same medication. The distinction comes down to dose and intent. Ozempic reaches a maximum of 1mg weekly for diabetes management. Wegovy escalates to 2.4mg weekly — and now up to 7.2mg with the HD formulation — because weight management requires a higher therapeutic level than blood sugar control alone.
Semaglutide works by activating the GLP-1 receptor, mimicking a hormone your body produces naturally after eating. That activation does several things simultaneously: it slows how quickly food moves through your digestive system, signals your brain that you’re full, and reduces the baseline intensity of hunger between meals. The effect on appetite for most patients is noticeable, not a white-knuckle suppression, but a genuine shift in how hunger feels day to day.
At the doses used in Wegovy, that effect is more pronounced than at the doses used in Ozempic. That’s why Wegovy consistently produces greater weight loss than Ozempic in comparative studies, even though they contain the same molecule.
Wegovy HD is a higher-dose injectable formulation of semaglutide at 7.2mg weekly, approved by the FDA. In clinical trials, patients who stayed on Wegovy HD achieved approximately 21% weight loss at 72 weeks.
For patients who reach the standard maintenance dose without sufficient results, Wegovy HD is a natural step worth discussing.
Standard injectable Wegovy follows a gradual five-stage escalation to the maintenance dose:
- Weeks 1-4: 0.25mg once weekly (starter dose)
- Weeks 5-8: 0.5mg once weekly
- Weeks 9-12: 1mg once weekly
- Weeks 13-16: 1.7mg once weekly
- Week 17 Onward: 2.4mg once weekly (standard maintenance dose)
Yes. Wegovy is the only GLP-1 medication FDA-approved to reduce the risk of major cardiovascular events in adults with obesity or overweight and established cardiovascular disease.
It’s also the only GLP-1 medication approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition closely associated with obesity. The breadth of Wegovy’s FDA-approved indications is unlike any other weight loss medication on the market.
Yes. The FDA approved an oral version of Wegovy in December 2025, making it the first GLP-1 medication available as a once-daily pill for weight loss. Clinical trials showed average weight loss of 16.6% of body weight over 64 weeks, comparable to the injectable version at standard doses.
For patients who prefer not to self-inject, this option makes Wegovy more accessible than it’s ever been. Want to learn more. Check out our weight loss pill page to discover your oral weight loss options.
Weight Loss That Was Designed to Last
Wegovy is the most purpose-built weight loss medication on the market, and it’s advancing faster than any of its competitors right now. If you’re ready to have a conversation about whether it belongs in your plan, our team is here for you. In-person consultations at our Birmingham office and telehealth visits for Alabama patients are both available.
